--- title: "Weekly Recap | CSPC PHARMA +4.97%, earnings and pipeline drive rally" type: "News" locale: "en" url: "https://longbridge.com/en/news/296673998.md" description: "CSPC PHARMA (1093.HK) ended the week at HK$9.19, up 4.97% and comfortably ahead of the Hang Seng Index, which gained 2.19% over the same four-day trading week. The move was a clear surge-and-fade: Monday and Tuesday saw the stock consolidating in a tight HK$8.6–8.9 range, before Wednesday’s flood of catalysts sent it gapping sharply higher. The session touched an intraday high of HK$10.17, with the day’s amplitude reaching over 17%, before settling at HK$9.52." datetime: "2026-08-22T06:47:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296673998.md) - [en](https://longbridge.com/en/news/296673998.md) - [zh-HK](https://longbridge.com/zh-HK/news/296673998.md) generator: "portal-rs" --- # Weekly Recap | CSPC PHARMA +4.97%, earnings and pipeline drive rally ## The Week CSPC PHARMA (1093.HK) ended the week at HK$9.19, up 4.97% and comfortably ahead of the Hang Seng Index, which gained 2.19% over the same four-day trading week. The move was a clear surge-and-fade: Monday and Tuesday saw the stock consolidating in a tight HK$8.6–8.9 range, before Wednesday’s flood of catalysts sent it gapping sharply higher. The session touched an intraday high of HK$10.17, with the day’s amplitude reaching over 17%, before settling at HK$9.52. Thursday saw modest profit-taking, pulling the close back to HK$9.19, but the stock still booked a solid weekly gain. Turnover ballooned to HK$6.58 billion, with average daily volume nearly double the 60-day median, signalling a sharp step-up in market participation. ## Key Events This week’s narrative centred on a one-two punch of pipeline progress and a blowout earnings report. Early in the week, the company flagged a US$30 million upfront payment from AstraZeneca and the Phase I start of SYS6063. The tempo accelerated on Wednesday: the first centre in China was initiated for the Phase Ib/II trial of SYS6090 in hepatocellular carcinoma, and concurrently, CSPC Pharma unveiled its 2026 interim results. Attributable profit more than doubled to RMB 6.09 billion, while revenue climbed 40.1% to RMB 18.59 billion, driven by robust finished-drug sales and licensing income. The board declared an interim dividend of HK$0.18 per share, a 28.6% year-on-year increase. A broader sector tailwind also arrived midweek, as Moderna’s positive Phase III cancer-vaccine data lifted sentiment across innovative drug names, with CSPC’s shares spiking more than 15% intraday. Elsewhere, the NMPA accepted the new drug application for anbenitamab plus docetaxel (albumin-bound) in first-line advanced breast cancer, and subsidiary CSPC Innovation Pharmaceutical filed unaudited financials, rounding out a busy week of disclosures. ## Analyst Ratings Brokers moved quickly to update their views after the earnings release. The consensus rating across 23 analysts remains a ‘buy’, with 3 strong buys, 16 buys, 3 overweights, 2 holds, 1 underweight and 1 sell. The consensus target price sits at HK$12.31, implying roughly 34% upside from the week’s close. The range, however, is unusually wide: from HK$7.20 at the low end to HK$19.36 at the high end, underscoring divergent views on the pipeline’s ultimate value. Within the pharmaceutical sector of 29 peers, CSPC Pharma ranks first in composite analyst rating. ## The Week Ahead With the earnings catalyst now behind, the market’s attention is likely to pivot to management’s commentary on the full-year outlook and pipeline milestones. The Phase Ib/II trial of SYS6090 has just enrolled its first patient; any updates on enrolment pace or data-read timelines will be closely watched. The NMPA review of the anbenitamab combination therapy is also a fresh regulatory event that could move the needle. Beyond company-specific events, the sustainability of the Hang Seng Index’s move back above 26,000 will be a key macro factor influencing the risk appetite for heavyweight healthcare names. ## In Short CSPC Pharma delivered a textbook catalyst-driven week: stellar earnings and pipeline execution fuelled the rally, yet the intraday reversal from HK$10.17 signals that some investors used the strength to lock in gains. The stock trades at about 12.4x P/E, and the consensus target implies a comfortable cushion, but the wide spread between the highest and lowest Street targets shows deep disagreement on the timing and magnitude of pipeline monetisation. The next leg of the story will depend on whether clinical data and global licensing deals can convert potential into proof. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [01093.HK](https://longbridge.com/en/quote/01093.HK.md) ## Related News & Research - [CSPC PHARMA Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md) - [CSPC PHARMA 1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md) - [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md) - [M Stanley Raises CSPC PHARMA TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md) - [CSPC says FDA clears RSV vaccine candidate SYS 6057 for US clinical trial](https://longbridge.com/en/news/296903628.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**